BEAM Stock Price and Chart — CAPITALCOM:BEAM — TradingView

Overview

News Ideas Discussions Seasonals

BEAM chart

Key facts today

Beam Therapeutics has started dosing the fourth group in its Phase 1/2 trial for BEAM-302, aimed at alpha-1 antitrypsin deficiency, following positive initial results and U.S. IND approval.

Analyze the impact Analyze the impact

Ideas

See all ideas

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.